Ye Che

Ye Che

Auto-generated profile, based on publicly available information

Ye Che

Department of Discovery Sciences, Pfizer Inc, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Nature
Verified
Journal Article
Closed access
PDF file
AVAnnette B. Vogel
Annette B. Vogel
IKIsis Kanevsky
Isis Kanevsky
YCYe Che
Ye Che
KSKena A Swanson
Kena A Swanson
AMAlexander Muik
Alexander Muik
USUgur Sahin
Ugur Sahin

16 November 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JSJames Schiemer
James Schiemer
RHReto Horst
Reto Horst
YMYilin Meng
Yilin Meng
JMJustin I. Montgomery
Justin I. Montgomery
YXYingrong Xu
Yingrong Xu
MCMatthew F. Calabrese
Matthew F. Calabrese

5 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
YLYuhang Liu
Yuhang Liu
KHKyle P. Heim
Kyle P. Heim
YCYe Che
Ye Che
XCXiaoyuan Chi
Xiaoyuan Chi
XQXiayang Qiu
Xiayang Qiu
XYXinzhen Yang
Xinzhen Yang
Prefusion human cytomegalovirus glycoprotein B structure reveals the structural basis for membrane fusion.

26 April 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYe Che
Ye Che
AGAlexey V. Gribenko
Alexey V. Gribenko
XSXi Song
Xi Song
LHLuke D. Handke
Luke D. Handke
KEKari S. Efferen
Kari S. Efferen
KSKena A Swanson
Kena A Swanson
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum-neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.

5 October 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
KFKathleen A. Farley
Kathleen A. Farley
MKMartin R. M. Koos
Martin R. M. Koos
YCYe Che
Ye Che
RHReto Horst
Reto Horst
CLChris Limberakis
Chris Limberakis
RGRoberto R. Gil
Roberto R. Gil

5 October 2021 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
KFKathleen A. Farley
Kathleen A. Farley
MKMartin R. M. Koos
Martin R. M. Koos
YCYe Che
Ye Che
RHReto Horst
Reto Horst
CLChris Limberakis
Chris Limberakis
RGRoberto R. Gil
Roberto R. Gil